| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Drugabuse Sciences, Inc. |
| 1430 O'Brien Drive, Menlo Park, CA 94025 * (650) 462-1000 |
| Business Description | The company is the first biotechnology company dedicated to developing and marketing novel therapies for alcohol and drug abusers. |
|
Filing Information IPO has been | |||
| To Trade As | DASI (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 2/3/00 |
| Domestic Shares Filed | 4,000,000 | Filing Range | $8.00 - $9.00 |
| Foreign Shares Filed | 0 | Offering Amount | $34,000,000 |
| Company Shares | 4,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 14,735,260 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| UBS Warburg LLC | Lead Manager | |
| ABN Amro Roth | Co-manager | (212) 314-1080 |
| PaineWebber Incorporated | Co-manager | (212) 713-2626 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 9/30/98 | 9/30/99 | |||
| Revenues | - | - | - | - | 0.811 | 0.631 | 0.921 |
| Income from Oper. | - | - | - | -1.382 | -1.077 | -0.644 | -2.857 |
| Net Income | - | - | - | -1.300 | -0.996 | -0.607 | -2.865 |
| E.P.S | - | - | - | -0.610 | -0.470 | -0.290 | -1.350 |
| Revenue Growth (%) | - | - | - | - | 46.09 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -1.14 | -0.66 | -2.60 | ||||
| Cash Flow - Inv. | -0.03 | -0.02 | - | ||||
| Cash Flow - Fin. | -0.10 | -0.05 | 5.17 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/99 | Financial Ratios | ||||
| Total Assets | 4.96 | Current Assets | 4.54 | Current Ratio | 5.44 |
| Total Liab. | 0.71 | Current Liab. | 0.84 | Debt Ratio | 14.41% |
| Total Equity | 4.24 | Working Cap. | 3.71 | Debt to Equity Ratio | 0.17 |
| Cash | 3.61 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Gunderson Dettmer Stough Villeneuve Franklin |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Phillippe Pouletty, M.D. | 23.93 | |
| Entities affiliated with Partech International | 12.59 | |
| 3i Group PLC | 7.90 | |
| Nomura | 5.88 | |
| Entities affiliated with ABN-Amro | 5.53 | |
| CDC-Innovations | 4.73 | |
| Parnib Belgie N.V. | 4.70 | |
| Note: represents ownership of 5% or more prior to the offering. | ||